OncoMatch/Clinical Trials/NCT06679985
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Is NCT06679985 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Casdozokitug and Toripalimab for hepatocellular carcinoma.
Treatment: Casdozokitug · Toripalimab · Bevacizumab — The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Prior therapy
Cannot have received: systemic therapy
Cannot have received: anti-il-27 antibody or anti-il-27-targeted therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic - Scottsdale · Scottsdale, Arizona
- University of Arizona - Cancer Center · Tucson, Arizona
- Beverly Hills Cancer Center · Beverly Hills, California
- City of Hope · Duarte, California
- City of Hope at Irvine Lennar · Irvine, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify